{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:00:37Z","timestamp":1790820037216,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ijgc.2025.102025","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T23:50:23Z","timestamp":1753833023000},"page":"102025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights from the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-8940","authenticated-orcid":false,"given":"Let\u00edcia Vecchi","family":"Leis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-7594","authenticated-orcid":false,"given":"Mariana Carvalho","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2907-4605","authenticated-orcid":false,"given":"J\u00e9ssica Monteiro","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-0100","authenticated-orcid":false,"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.ijgc.2025.102025_bib1","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10421","key":"10.1016\/j.ijgc.2025.102025_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.102025_bib3","volume":"10","author":"De Giorgi","year":"2025","journal-title":"ESMO Open"},{"issue":"27","key":"10.1016\/j.ijgc.2025.102025_bib4","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1200\/JCO.19.00314","article-title":"Advances in the management of platinum-sensitive relapsed ovarian cancer","volume":"37","author":"Bouberhan","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijgc.2025.102025_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105205","article-title":"76MO Final analysis of the single-arm phase II PICCOLO trial of mirvetuximab soravtansine-gynx (MIRV) in folate receptor alpha (FR\u03b1)-positive, third-line and later (3L+), recurrent platinum-sensitive ovarian cancer (PSOC)","volume":"10","author":"Secord","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2025.102025_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105201","article-title":"72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICCOLO clinical trial","volume":"10","author":"Oaknin","year":"2025","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.ijgc.2025.102025_bib7","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/cancers14184414","article-title":"Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting","volume":"14","author":"Romeo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"34","key":"10.1016\/j.ijgc.2025.102025_bib8","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, Phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102025_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105204","article-title":"75MO Efficacy and safety of Rucaparib maintenance treatment in patients from Athena-MONO\/GOG-3020\/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency","volume":"10","author":"Oaknin","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2025.102025_bib10","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2023.09.1926","article-title":"747MO First results from the ENGOT-GYN2\/GOG-3051\/BOUQUET phase II biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent\/recurrent rare epithelial ovarian cancer (eOC)","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102025_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105199","article-title":"69O Novel regimens for persistent\/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2\/GOG-3051\/BOUQUET phase II study results","volume":"10","author":"Ray-Coquard","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102025_bib12","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-08-2131","article-title":"Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1\/DUSP1 in ovarian tissues","volume":"15","author":"Melhem","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"10496","key":"10.1016\/j.ijgc.2025.102025_bib13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.102025_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105332","article-title":"70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): secondary endpoints","volume":"10","author":"Lorusso","year":"2025","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102025_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101974","article-title":"Beyond resistance: redefining the therapeutic landscape of platinum-resistant ovarian cancer","volume":"35","author":"de Oliveira","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102025_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101659","article-title":"Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial","volume":"35","author":"Lima Feldmann","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102025_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.102025_bib18","first-page":"1","article-title":"Prognostic value of PDL1 expression and correlation with HRD status in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1\/ENGOT-ov25 trial, a GINECO study","volume":"10","author":"Treilleux","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.102025_bib19","first-page":"1","article-title":"Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): opportunities for targeted treatment strategies","volume":"10","author":"Hamagawa","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ijgc.2025.102025_bib20","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1136\/ijgc-2024-IGCS.13","article-title":"LB007\/#1548 Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"34","author":"Banerjee","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.102025_bib21","first-page":"1","article-title":"Blood ctDNA vs tumor tissue screening for the detection of KRAS mutations in low-grade serous ovarian cancer","volume":"10","author":"Van Nieuwenhuysen","year":"2025","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2025.102025_bib22","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.102025_bib23","first-page":"1","article-title":"Clinical features and outcomes of patients with metastatic POLE-mutated endometrial cancer: a rare and understudied molecular subtype","volume":"10","author":"Frenel","year":"2025","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:22:54Z","timestamp":1790817774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25011454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1048891X25011454"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102025","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102025"}}